ANNOUNCEMENT

These 11 companies will be featured in the MedCity ENGAGE Innovation Showcase June 5-6 in Washington, D.C.

Topic: POZN

Pozen migraine drug licensed to Desitin for commercialization in Europe

Pozen migraine drug licensed to Desitin for commercialization in Europe

May 8, 2012 11:11 am by | 0 Comments

The migraine headache treatment developed by Pozen (NASDAQ:POZN) now has a partner for commercialization in Europe.Pozen licensed the compound MT 400 to German central nervous system therapies company Desitin in ... Read more
How arthritis drug Vimovo could ease Pozen’s PA32540 regulatory pain

How arthritis drug Vimovo could ease Pozen’s PA32540 regulatory pain

May 1, 2012 5:26 pm by | 0 Comments

Osteoarthritis drug Vimovo‘s sales disappointed early and its U.S. prescriptions have declined as of late, but for all of those commercialization pains, the drug has become an unexpected regulatory beacon ... Read more
FDA concerns may limit cardiovascular approval of Pozen’s safer aspirin

FDA concerns may limit cardiovascular approval of Pozen’s safer aspirin

April 30, 2012 2:52 pm by | 0 Comments

Pozen (NASDAQ:POZN), now prepping to file a new drug application for its safer form of aspirin, has run into a slight regulatory headache.The company had looked on track way for ... Read more
Safer aspirin is strong in phase 3; Pozen plans 3Q NDA filing

Safer aspirin is strong in phase 3; Pozen plans 3Q NDA filing

March 22, 2012 11:18 am by | 0 Comments

The delayed-release aspirin compound that Pozen (NASDAQ:POZN) has developed to protect against cardiovascular disease showed in clinical trials that it causes fewer ulcers compared to aspirin alone.With those positive phase ... Read more
How arthritis drug Vimovo shaped POZN’s strategy on its heart drug

How arthritis drug Vimovo shaped POZN’s strategy on its heart drug

February 28, 2012 3:03 pm by | 0 Comments

Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach, was ... Read more
Why Gatorade might be an elixir for pharma marketing’s digital health ills

Why Gatorade might be an elixir for pharma marketing’s digital health ills

February 14, 2012 11:40 am by | 1 Comments

For a glimpse into social media’s coming role in pharmaceutical sales and marketing, and the digital health of tomorrow, consider its use in Gatorade’s marketing today.The Gatorade Company maintains a ... Read more
Aspirin reimagined and Pozen’s new drug partnership possibilities

Aspirin reimagined and Pozen’s new drug partnership possibilities

January 27, 2012 7:00 am by | 0 Comments

As drug partnering auditions go, Pozen (NASDAQ:POZN) has played this role before: The small drug developer flirts with a large pharmaceutical company who has the resources and the reach to ... Read more
Three lessons from two deals: POZN’s takeaways from drug partnerships

Three lessons from two deals: POZN’s takeaways from drug partnerships

January 27, 2012 7:00 am by | 0 Comments

Pozen (NASDAQ:POZN) CEO John Platchetka likens the drug partnering process to a relay race. One runner at full speed finishes and hands the baton to another runner at full speed ... Read more
Pozen strikes manufacturing pact with Patheon for heart drug

Pozen strikes manufacturing pact with Patheon for heart drug

December 21, 2011 10:52 am by | 0 Comments

The new cardiovascular drug being developed by Pozen (NASDAQ:POZN) does not yet even have a name, but it now has a manufacturer to produce it once it secures U.S. Food ... Read more
Why Pozen sold Treximet royalty rights and what it means for POZN’s pipeline

Why Pozen sold Treximet royalty rights and what it means for POZN’s pipeline

November 28, 2011 12:01 pm by | 1 Comments

To understand why Pozen (NASDAQ:POZN) sold future U.S. royalty rights for migraine drug Treximet, its lead revenue-generating product, it helps to understand what the company is doing with its drug ... Read more
Arthritis drug Vimovo’s slow sales are a pain to Pozen

Arthritis drug Vimovo’s slow sales are a pain to Pozen

November 4, 2011 1:35 pm by | 1 Comments

If you only looked at Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance.Although Chapel Hill, ... Read more
Change of heart: Why Pozen now wants to partner its cardiovascular drug

Change of heart: Why Pozen now wants to partner its cardiovascular drug

October 4, 2011 6:34 pm by | 0 Comments

Digital drug marketing has been pharmaceutical company Pozen‘s (NASDAQ:POZN) mantra for much of this year. The Chapel Hill, North Carolina-based company has made clear that when it goes to market ... Read more
Pozen’s digital drug marketing plan: A prescription for the pharma industry?

Pozen’s digital drug marketing plan: A prescription for the pharma industry?

September 16, 2011 4:32 pm by | 0 Comments

The digital communication consumers favor today to discuss retail products and food might have more to say about the future of pharmaceutical marketing than the still-ubiquitous television commercials promoting the ... Read more
Generic drugs firms appeal patent ruling on Pozen migraine drug

Generic drugs firms appeal patent ruling on Pozen migraine drug

September 8, 2011 10:08 am by | 0 Comments

Pozen‘s (NASDAQ:POZN) patent fight to protect its migraine headache drug Treximet is not yet over.The Chapel Hill, North Carolina-based pharmaceutical company won a patent litigation court victory last month when ... Read more
Migraine drug patents for Pozen’s Treximet upheld by judge

Migraine drug patents for Pozen’s Treximet upheld by judge

August 8, 2011 11:49 am by | 0 Comments

Migraine headache treatment Treximet, developed by pharmaceutical company Pozen (NASDAQ:POZN), has won a patent victory against generics companies looking to introduce their versions of the drug.A federal judge in Texas ... Read more